DUBLIN--(BUSINESS WIRE)--The "Global Renal Biomarker Market - Segmented by Biomarker Type, Diagnostic Technique, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global renal biomarker market is expected to register a good CAGR during 2018-2023 (the forecast period).
Kidney disease is a major cause of deaths worldwide. With the increasing incidences of chronic kidney diseases, especially, among the geriatric population, the need for novel biomarkers for early detection of the disease is increasing.
Currently, kidney-related issues are increasing across the world. The global prevalence rate is increasing every year. Therefore, the market for renal biomarkers is expected to grow, as they are helpful for the detection of kidney diseases. Additionally, other factors, such as high prevalence of diabetes and high blood pressure, which lead to renal diseases, along with rapid technological advances in the field of genetics, are driving the market growth.
The US to Lead the Market in North America: In 2017, the US renal biomarker market held the largest market share in North America, due to the presence of high-quality healthcare system, along with the prevalence rate of kidney diseases being high in this region.
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc.
- Abbott Molecular Inc.
- Bioporto A/S
- Astute Medical Inc.
- Randox Laboratories Ltd
- Siemens Healthcare Diagnostics Inc.
- Alere Inc.
- F. Hoffmann-La Roche AG
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/9bxxmj/global_renal?w=4